PMID- 36199537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221007
IS  - 1000-9604 (Print)
IS  - 1993-0631 (Electronic)
IS  - 1000-9604 (Linking)
VI  - 34
IP  - 4
DP  - 2022 Aug 30
TI  - Clinical outcomes of atezolizumab in combination with etoposide/platinum for 
      treatment of extensive-stage small-cell lung cancer: A real-world, multicenter, 
      retrospective, controlled study in China.
PG  - 353-364
LID - 10.21147/j.issn.1000-9604.2022.04.04 [doi]
AB  - OBJECTIVE: Atezolizumab along with chemotherapy has prolonged the survival of 
      patients with extensive-stage small-cell lung cancer (ES-SCLC) worldwide, 
      although real-world (RW) data are lacking in China. This study was designed to 
      evaluate the efficacy and clinical outcomes of atezolizumab plus 
      etoposide/platinum (EP). METHODS: Data obtained in this retrospective study were 
      captured from six oncology units of five medical facilities from January 2019 to 
      April 2022. For first-line treatments, atezolizumab combined with EP vs. EP 
      alone, we primarily evaluated progression-free survival (PFS); other efficacy 
      indicators, including overall survival (OS), objective response rate (ORR), and 
      patterns of SCLC progression and adverse events (AEs) were assessed. RESULTS: The 
      primary analysis included data from 225 patients, of whom 133 received EP along 
      with atezolizumab (atezolizumab group) and 92 received EP alone (EP group). The 
      PFS duration of the atezolizumab group [7.10 months; 95% confidence interval (95% 
      CI), 6.53-9.00] exceeded that of the EP group (6.50 months; 95% CI, 4.83-7.53). 
      Overall, the hazard ratio (HR) was 0.69 (95% CI, 0.49-0.97) (P=0.029); 
      particularly, the HR was 0.54 (95% CI, 0.36-0.80) among patients undergoing >/=4 
      chemotherapy cycles and 0.33 (95% CI, 0.20-0.56) among individuals with 
      atezolizumab maintenance. The ORR and disease-control rate (DCR) were similar 
      between the two groups. Because of incomplete OS data, the median OS was not 
      determined for either group. Bone marrow suppression was the most common AE 
      detected (58.6%) in the atezolizumab group. Immune-related AEs occurred in 19 
      patients in the atezolizumab group (14.3%), with only one case of grade 3 
      encephalitis. CONCLUSIONS: This RW study in China demonstrated improved clinical 
      outcomes of atezolizumab along with EP for ES-SCLC, particularly in the 
      chemosensitive population. These results align with the results of the IMpower133 
      study, although the impact of this treatment modality on OS warrants additional 
      follow-up studies.
CI  - (c) Chinese Journal of Cancer Research. All rights reserved.
FAU - Chen, Hanxiao
AU  - Chen H
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer 
      Hospital & Institute, Beijing 100142, China.
FAU - Ma, Xiangjuan
AU  - Ma X
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department II of Thoracic Oncology, Peking University Cancer 
      Hospital & Institute, Beijing 100142, China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Pneumology, Shandong Cancer Hospital and Institute, Shandong First 
      Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
FAU - Yang, Yu
AU  - Yang Y
AD  - Department of Oncology, the 2nd Affiliated Hospital of Harbin Medical University, 
      Harbin 150001, China.
FAU - Fang, Yong
AU  - Fang Y
AD  - Department of Oncology, Sir Run Run Shaw Hospital Zhejiang University School of 
      Medicine, Hangzhou 310020, China.
FAU - Wang, Liping
AU  - Wang L
AD  - Department of Oncology, Baotou Cancer Hospital, Baotou 014030, China.
FAU - Fang, Jian
AU  - Fang J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department II of Thoracic Oncology, Peking University Cancer 
      Hospital & Institute, Beijing 100142, China.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer 
      Hospital & Institute, Beijing 100142, China.
FAU - Zhuo, Minglei
AU  - Zhuo M
AD  - Key Laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer 
      Hospital & Institute, Beijing 100142, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin J Cancer Res
JT  - Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
JID - 9315242
PMC - PMC9468015
OTO - NOTNLM
OT  - Real-world study
OT  - atezolizumab
OT  - extensive-stage SCLC
EDAT- 2022/10/07 06:00
MHDA- 2022/10/07 06:01
PMCR- 2022/08/30
CRDT- 2022/10/06 02:08
PHST- 2022/03/03 00:00 [received]
PHST- 2022/07/13 00:00 [accepted]
PHST- 2022/10/06 02:08 [entrez]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/10/07 06:01 [medline]
PHST- 2022/08/30 00:00 [pmc-release]
AID - cjcr-34-4-353 [pii]
AID - 10.21147/j.issn.1000-9604.2022.04.04 [doi]
PST - ppublish
SO  - Chin J Cancer Res. 2022 Aug 30;34(4):353-364. doi: 
      10.21147/j.issn.1000-9604.2022.04.04.